The Quigley Corporation's, wholly owned subsidiary Quigley Pharma received four additional investigational new animal drug (INAD) numbers, from the Center for Veterinary Medicine of the Food and Drug Administration.

The company's naturally derived QR-441A can now be tested upon dogs, cats, horses and companion birds. The formula has previously been tested in a combination of ten efficacious in-vitro and in-vivo studies (in-vivo studies were conducted on ferrets), under the direction of Professor John Oxford, Dr. Rob Lambkin and Sebastien Bossuyt at Retroscreen Virology, Queen Mary's School of Medicine & Dentistry, University of London, UK, claims a company release.

Dr. Richard Rosenbloom, Quigley Pharma's chief operations officer stated, "Prompted by the new data upon the H3N8 Equine (horse) flu's cross over to dogs, we can not only test QR-441A upon chickens, turkeys and ducks but have received permission from the FDA to test upon companion animals: horses, dogs, cats and birds. We believe that the mechanism of action of this all-natural compound may prevent transmission within species as well as to other species. Pets, especially dogs, have the most intimate contact with humans on a daily basis. In addition to our concerns for our pet's health, the potential for human infection has to be considered."

Quigley Pharma will be coordinating various protocols with the Center for Veterinary Medicine to obtain the guidance for the best route to a drug license for its potential drug. These studies shall be conducted in biosafety level 3 facilities across the United States and perhaps overseas.

The Quigley Corporation is the leading developer and marketer of diversified health products. The company's proven success in launching first-in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.